One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study
The Swedish Lucentis Quality Registry is a 12-month, open-label, observational, prospective, and retrospective study of ranibizumab administration for wet AMD. Visual acuity (VA) was measured with Snellen or ETDRS chart in 370 patients (66.8% women; age range 46–93 years). In total, a mean of 4.7±1...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2011/405724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850160363064000512 |
|---|---|
| author | Lars Hjelmqvist Charlotte Lindberg Pär Kanulf Henrik Dahlgren Ingrid Johansson Annica Siewert |
| author_facet | Lars Hjelmqvist Charlotte Lindberg Pär Kanulf Henrik Dahlgren Ingrid Johansson Annica Siewert |
| author_sort | Lars Hjelmqvist |
| collection | DOAJ |
| description | The Swedish Lucentis Quality Registry is a 12-month, open-label, observational, prospective, and retrospective study of ranibizumab administration for wet AMD. Visual acuity (VA) was measured with Snellen or ETDRS chart in 370 patients (66.8% women; age range 46–93 years). In total, a mean of 4.7±1.6 injections per patient (range 1–10) was given to month 12. Mean VA score was 58.3±12.2 letters before treatment, 63.3±12.5 after 3 injections (Δ4.9±10.1 letters from baseline), and 59.3±16.2 at 12 months (Δ1.0±13.6). VA score from baseline to month 12 was stable in 74.4% of patients, improved by 15 letters/3 lines or more in 14.7%, and decreased by ≥15 letters/3 lines in 10.9% of patients. With a mean of 4.7 ranibizumab injections per patient per year, mean VA was stabilised but not increased. To maintain the initial gain seen after the first three injections, an average of 1.8±1.5 additional injections does not appear to be adequate. |
| format | Article |
| id | doaj-art-b6ee206a9db74916a633aedd63fb2f1d |
| institution | OA Journals |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-b6ee206a9db74916a633aedd63fb2f1d2025-08-20T02:23:09ZengWileyJournal of Ophthalmology2090-004X2090-00582011-01-01201110.1155/2011/405724405724One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre StudyLars Hjelmqvist0Charlotte Lindberg1Pär Kanulf2Henrik Dahlgren3Ingrid Johansson4Annica Siewert5St. Erik's Eye Hospital, Karolinska Institutet, Polhemsgatan 50, 11282 Stockholm, SwedenDepartment of Ophthalmology, Lund University Hospital, 22185 Lund, SwedenDepartment of Ophthalmology, Ryhov Hospital, 55185 Jönköping, SwedenDepartment of Ophthalmology, Södersjukhuset, 11883 Stockholm, SwedenDepartment of Ophthalmology, Örebro University Hospital, 70185 Örebro, SwedenMedical Department, Novartis Sweden AB, 18311 Täby, SwedenThe Swedish Lucentis Quality Registry is a 12-month, open-label, observational, prospective, and retrospective study of ranibizumab administration for wet AMD. Visual acuity (VA) was measured with Snellen or ETDRS chart in 370 patients (66.8% women; age range 46–93 years). In total, a mean of 4.7±1.6 injections per patient (range 1–10) was given to month 12. Mean VA score was 58.3±12.2 letters before treatment, 63.3±12.5 after 3 injections (Δ4.9±10.1 letters from baseline), and 59.3±16.2 at 12 months (Δ1.0±13.6). VA score from baseline to month 12 was stable in 74.4% of patients, improved by 15 letters/3 lines or more in 14.7%, and decreased by ≥15 letters/3 lines in 10.9% of patients. With a mean of 4.7 ranibizumab injections per patient per year, mean VA was stabilised but not increased. To maintain the initial gain seen after the first three injections, an average of 1.8±1.5 additional injections does not appear to be adequate.http://dx.doi.org/10.1155/2011/405724 |
| spellingShingle | Lars Hjelmqvist Charlotte Lindberg Pär Kanulf Henrik Dahlgren Ingrid Johansson Annica Siewert One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study Journal of Ophthalmology |
| title | One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study |
| title_full | One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study |
| title_fullStr | One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study |
| title_full_unstemmed | One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study |
| title_short | One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study |
| title_sort | one year outcomes using ranibizumab for neovascular age related macular degeneration results of a prospective and retrospective observational multicentre study |
| url | http://dx.doi.org/10.1155/2011/405724 |
| work_keys_str_mv | AT larshjelmqvist oneyearoutcomesusingranibizumabforneovascularagerelatedmaculardegenerationresultsofaprospectiveandretrospectiveobservationalmulticentrestudy AT charlottelindberg oneyearoutcomesusingranibizumabforneovascularagerelatedmaculardegenerationresultsofaprospectiveandretrospectiveobservationalmulticentrestudy AT parkanulf oneyearoutcomesusingranibizumabforneovascularagerelatedmaculardegenerationresultsofaprospectiveandretrospectiveobservationalmulticentrestudy AT henrikdahlgren oneyearoutcomesusingranibizumabforneovascularagerelatedmaculardegenerationresultsofaprospectiveandretrospectiveobservationalmulticentrestudy AT ingridjohansson oneyearoutcomesusingranibizumabforneovascularagerelatedmaculardegenerationresultsofaprospectiveandretrospectiveobservationalmulticentrestudy AT annicasiewert oneyearoutcomesusingranibizumabforneovascularagerelatedmaculardegenerationresultsofaprospectiveandretrospectiveobservationalmulticentrestudy |